Document is current
Any future updates will be listed below
-
Authors
Ho, Won Jin
Zhu, Qingfeng https://orcid.org/0000-0001-7871-3359
Durham, Jennifer
Popovic, Aleksandra
Xavier, Stephanie
Leatherman, James
Mohan, Aditya
Mo, Guanglan
Zhang, Shu
Gross, Nicole https://orcid.org/0000-0002-8936-207X
Charmsaz, Soren https://orcid.org/0000-0002-9148-9870
Lin, Dongxia
Quong, Derek
Wilt, Brad
Kamel, Ihab R.
Weiss, Matthew
Philosophe, Benjamin
Burkhart, Richard
Burns, William R.
Shubert, Chris
Ejaz, Aslam
He, Jin
Deshpande, Atul
Danilova, Ludmila https://orcid.org/0000-0003-2813-3094
Stein-O’Brien, Genevieve
Sugar, Elizabeth A.
Laheru, Daniel A.
Anders, Robert A.
Fertig, Elana J.
Jaffee, Elizabeth M. https://orcid.org/0000-0003-3841-6549
Yarchoan, Mark https://orcid.org/0000-0003-4401-0748
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01 CA212007, P50 CA062924, P50 CA062924, U01CA221007)
Emerson Collective Cancer Research Fund
Exelixis
Bristol-Myers Squibb
Bloomberg-Kimmel Institute for Cancer Immunotherapy
- License Information
-
More Information
Article History
Received: 3 November 2020
Accepted: 10 June 2021
First Online: 29 July 2021
Competing interests
: W.J.H. is a coinventor of patents with potential for receiving royalties from Rodeo Therapeutics, is a consultant for Exelixis and receives research funding from Sanofi. R.A.A. reports receiving a commercial research support from Bristol Myers Squibb and is a consultant/advisory board member for Bristol Myers Squibb, Merck, AstraZeneca, Incyte and RAPT Therapeutics. E.M.J. reports receiving a commercial research grant from Bristol Myers Squibb and Aduro Biotech and is a consultant/advisory board member for the Lustgarten Foundation, Parker Institute for Cancer Immunotherapy, CStone Pharmaceuticals, Dragonfly, Genocea, Achilles Therapeutics and Adaptive Biotechnologies; she is cofounder of Abmeta Biotech. M.Y. reports receiving research grants from Incyte, Bristol Myers Squibb and Exelixis and is a consultant for AstraZeneca, Eisai, Exelixis and Genentech. The other authors declare no competing interests.
